Telemedical home monitoring solution to analyze gait and fall in Parkinson's patients

A groundbreaking project for Parkinson's patients from the European Institute of Innovation and Technology Health (EIT Health) titled 'MoveIT' has now been launched under the lead of the Molecular-Neurological Department at Universitätsklinikum Erlangen in collaboration with researchers from Friedrich-Alexander-Universität Erlangen-Nürnberg and other European partners. Using telemedicine based on sensors placed in patients' shoes and attached to their upper body, researchers aim to analyze specific characteristics in the patient's gait and when they fall. 'In future, patients or carers will be able to be warned in time if a certain gait pattern indicates that a fall is likely', says lead researcher Prof. Dr. Jochen Klucken from the Molecular-Neurological Department at Universitätsklinikum Erlangen. The data gathered as part of the telemedical home monitoring solution is also to be made available for use in further research projects for the interdisciplinary care of Parkinson's patients based on medical engineering approaches. The project is planned to run for one year and has received funding of 500,000 euros from EIT Health.

'MoveIT' is just one of a number of research projects conducted by the consortium led by Prof. Klucken from the Molecular-Neurological Department at Universitätsklinikum Erlangen and Prof. Dr. Björn Eskofier from the Chair for Machine Learning and Data Analysis (Heisenberg professor) at FAU Erlangen-Nürnberg aimed at designing new digital care concepts for Parkinson's. These include another two EIT projects and a project funded by the Medical Valley Award (FallRiskPD) for assessing the risk of falls. The new EIT health project is to be run in close collaboration with the Fraunhofer Institute for Integrated Circuits (IIS) Erlangen, headed by Christian Weigand, in order to create the required IT infrastructure for improved communication between doctors, therapists, patients and technology and provide the best possible patient care. Other regional and European partners involved in the project are the University of Luxembourg, Radboudumc university medical center in Nijmegen, the Netherlands, Philips Research ITTM S.A. and Portabiles HealthCare Technologies GmbH (HCT). 'By working with various partners we are able to incorporate experience from other EU countries and the private sector into the digital medicine we are developing as part of our project', explains Prof. Klucken.

With more than 140 partners from 17 European countries, EIT Health is one of the largest health initiatives in the world. FAU Erlangen-Nürnberg is a core partner in the EIT Health consortium. The Fraunhofer IIS is also involved as an associate member. The aim of EIT Health is to promote research, entrepreneurial thinking and innovation in the areas of healthy living and active aging, thereby improving the quality of life, medical care and the health sector throughout Europe. The EIT Health initiative aims to develop innovative products, education services and other services to contribute to solving demographic challenges and optimizing healthcare in Europe. With a total project volume of more than 2 billion euros, up to 700 million of which comes from funding, ETI Health is one of the largest publicly funded health initiatives in the world. The project is set to receive 80 million euros of annual funding over the next seven to fifteen years.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research suggests no need for yellow fever vaccine booster after initial dose